These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25926090)

  • 1. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.
    Li Y; Bare LA; Bender RA; Sninsky JJ; Wilson LS; Devlin JJ; Waldman FM
    Mol Diagn Ther; 2015 Jun; 19(3):169-77. PubMed ID: 25926090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
    Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
    Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.
    Gallego CJ; Shirts BH; Bennette CS; Guzauskas G; Amendola LM; Horike-Pyne M; Hisama FM; Pritchard CC; Grady WM; Burke W; Jarvik GP; Veenstra DL
    J Clin Oncol; 2015 Jun; 33(18):2084-91. PubMed ID: 25940718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.
    Curl P; Vujic I; van 't Veer LJ; Ortiz-Urda S; Kahn JG
    PLoS One; 2014; 9(9):e107255. PubMed ID: 25198196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
    Govers TM; Caba L; Resnick MJ
    J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.
    Qu K; Pan Q; Zhang X; Rodriguez L; Zhang K; Li H; Ho A; Sanders H; Sferruzza A; Cheng SM; Nguyen D; Jones D; Waldman F
    J Mol Diagn; 2013 Nov; 15(6):790-5. PubMed ID: 23994118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer.
    Abbass IM; Sheinson DM; Shah A; Gondos A; Ogale S
    J Manag Care Spec Pharm; 2024 Jul; 30(7):649-659. PubMed ID: 38950160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention.
    Hart MR; Garrison LP; Doyle DL; Jarvik GP; Watkins J; Devine B
    Value Health; 2019 Nov; 22(11):1231-1239. PubMed ID: 31708059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
    Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
    Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panel sequencing melanomas.
    Griewank KG; Schadendorf D
    J Invest Dermatol; 2015 Feb; 135(2):335-336. PubMed ID: 25573045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of carotid arteries in symptomatic patients: cost-effectiveness of diagnostic strategies.
    Buskens E; Nederkoorn PJ; Buijs-Van Der Woude T; Mali WP; Kappelle LJ; Eikelboom BC; Van Der Graaf Y; Hunink MG
    Radiology; 2004 Oct; 233(1):101-12. PubMed ID: 15333770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer.
    Bentley TG; Schroeder BE; Schnabel CA; Erlander MG; Hsiao WC; Ortendahl JD; Broder MS
    J Med Econ; 2014 Aug; 17(8):527-37. PubMed ID: 24689556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of open and endovascular revascularization for chronic mesenteric ischemia in a clinical decision model.
    Hogendoorn W; Hunink MG; Schlösser FJ; Moll FL; Muhs BE; Sumpio BE
    J Vasc Surg; 2014 Sep; 60(3):715-25.e2. PubMed ID: 24721175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
    Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
    BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
    J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.